Abbott Laboratories (ABT) Tops Q4 EPS by 4c; Raises FY12 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $98.16 -1.94%
Revenue Growth %: +14.2%
Financial Fact:
Dilutive Common Stock Options and Awards (in shares): 0
Today's EPS Names:
TAYD, TMQ, OMH, More
Revenue Growth %: +14.2%
Financial Fact:
Dilutive Common Stock Options and Awards (in shares): 0
Today's EPS Names:
TAYD, TMQ, OMH, More
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q4 EPS of $1.03, $0.04 better than the analyst estimate of $0.99. Revenue for the quarter came in at $9.46 billion versus the consensus estimate of $9.35 billion.
Abbott Laboratories sees FY2012 EPS of $5.00-$5.10, versus prior guidance of $4.95-$5.05 and the consensus of $5.01.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Abbott Laboratories sees FY2012 EPS of $5.00-$5.10, versus prior guidance of $4.95-$5.05 and the consensus of $5.01.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- Barclays Starts Abbott Labs (ABT) at Overweight
- Neogen stock up 8% on better-than-expected Q1 results, guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
